NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $16.35 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.59 +0.24 (+1.49%) As of 05/22/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avalo Therapeutics Stock (NASDAQ:AVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$16.02▼$17.0150-Day Range$12.86▼$22.8752-Week Range$3.43▼$24.27Volume1.32 million shsAverage Volume2.79 million shsMarket Capitalization$859.52 millionP/E RatioN/ADividend YieldN/APrice Target$48.13Consensus RatingModerate Buy Company Overview Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments. Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction. These clinical and preclinical assets are supported by a broader research portfolio exploring additional targets in inflammation, tissue remodeling and metabolic regulation. Avalo conducts in-house research at its headquarters in Redwood City, California, and collaborates with academic and industry partners across North America and Europe. Founded in 2014, Avalo Therapeutics has assembled a management team with deep expertise in drug discovery, clinical development and commercialization. The leadership includes executives and scientists who have held senior roles at leading pharmaceutical and biotechnology firms, providing strategic guidance and operational experience as the company advances its pipeline. Avalo’s governance structure and advisory board further support rigorous scientific evaluation and cultural alignment with industry best practices. With its integrated research capabilities, external partnerships and a focused pipeline of innovative candidates, Avalo Therapeutics aims to advance multiple programs toward late-stage clinical trials and ultimately deliver new treatment options for patients suffering from chronic cardiometabolic and inflammatory disorders.AI Generated. May Contain Errors. Read More Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreAVTX MarketRank™: Avalo Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 239th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAvalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAvalo Therapeutics has a consensus price target of $48.13, representing about 194.3% upside from its current price of $16.35.Amount of Analyst CoverageAvalo Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($2.72) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 12.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.46% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 9.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentAvalo Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Avalo Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,501,346.00 in company stock.Percentage Held by Insiders4.46% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTX Stock News HeadlinesAvalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 24 at 4:25 AM | americanbankingnews.comAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)May 22 at 4:01 PM | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Theravance Biopharma (NASDAQ:TBPH) and Avalo Therapeutics (NASDAQ:AVTX) Financial ComparisonMay 19, 2026 | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at WedbushMay 15, 2026 | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens JmpMay 15, 2026 | americanbankingnews.comInsider Selling: Avalo Therapeutics (NASDAQ:AVTX) Insider Sells 75,063 Shares of StockMay 8, 2026 | insidertrades.comAvalo Therapeutics (NASDAQ:AVTX) CFO Sells $110,715.22 in StockMay 2, 2026 | insidertrades.comSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $18.16 at the beginning of 2026. Since then, AVTX shares have decreased by 10.0% and is now trading at $16.35. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Wednesday, May, 13th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. When did Avalo Therapeutics' stock split? Shares of Avalo Therapeutics reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Who are Avalo Therapeutics' major shareholders? Top institutional shareholders of Avalo Therapeutics include Affinity Asset Advisors LLC (4.57%), Bank of America Corp DE (2.19%), Orbimed Advisors LLC (1.62%) and Jennison Associates LLC (1.76%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Paul Varki, Mittie Doyle, June Sherie Almenoff and Christopher Ryan Sullivan. View institutional ownership trends. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN). Company Calendar Last Earnings5/13/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AVTX's financial health is in the Green zone, according to TradeSmith. AVTX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees40Year Founded2015Price Target and Rating Average Price Target for Avalo Therapeutics$48.13 High Price Target$60.00 Low Price Target$34.00 Potential Upside/Downside+194.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($5.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.26 million Net MarginsN/A Pretax Margin-143,340.69% Return on Equity-97.54% Return on Assets-72.42% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.66 Sales & Book Value Annual Sales$60 thousand Price / Sales14,325.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book12.58Miscellaneous Outstanding Shares52,570,000Free Float50,222,000Market Cap$859.52 million OptionableNot Optionable Beta0.78 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AVTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
